Efavirenz
Efavirenz also known by the brand name Sustiva, is a non-nucleotide reverse transcriptase inhibitor used in the treatment and prevention of human immunodeficiency virus infections. Efavirenz is notable for having a strange array of effects, many resembling psychedelics, as well as an extremely unique pharmacological profile and structure.
Efavirenz | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Chemical Nomenclature | |||||||||||||||||||||
Common names | Efavirenz, Sustiva | ||||||||||||||||||||
Systematic name | (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one | ||||||||||||||||||||
Class Membership | |||||||||||||||||||||
Psychoactive class | Psychedelic | ||||||||||||||||||||
Chemical class | Benzoxazine | ||||||||||||||||||||
Routes of Administration | |||||||||||||||||||||
|
|||||||||||||||||||||
Interactions | |||||||||||||||||||||
MAOIs | |||||||||||||||||||||
Serotonin releasers | |||||||||||||||||||||
SSRIs | |||||||||||||||||||||
5-HTP |
Summary sheet: Efavirenz |
Chemistry
Unlike most psychedelics, efavirenz is not a tryptamine, phenethylamine or lysergamide. Efavirenz is classified as a benzoxazine and has several different moieties which give it a unique pharmacological profile. On the two position of the benzoxazine ring, efavirenz has a ketone attached. Efavirenz also has a trifluoromethyl group as well as a cyclopropane ring. The empirical formula of efavirenz is C14H9ClF3NO2 and has a molar mass of 315.675 grams per mole.[2]
Pharmacology
Pharmacologically, efavirenz is primarily classified as a non-nucleotide reverse transcriptase inhibitor, or NNRTI. Reverse transcriptase is an enzyme found in several viral species that is a type of DNA polymerase and nuclease that allows viruses like hepatitis and human immunodeficiency virus to transcribe viral RNA into DNA.
Unlike most non-nucleotide reverse transcriptase inhibitors, efavirenz is also a 5-HT2A partial agonist, similar to LSD. Additionally, efavirenz is a serotonin and dopamine reuptake inhibitor and a vesicular monoamine transporter 2 inhibitor. Efavirenz also acts as a GABAA positive allosteric modulator, similar to benzodiazepines and barbiturates.[3] Efavirenz has a bioavailability of about 40-45% when it is taken on an empty stomach.
Efavirenz is known to cause a false-positive for cannabis on some urine tests.[4]
Subjective effects
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects will rarely (if ever) occur all at once, but heavier dosages will increase the chances and are more likely to induce a full range of effects.
Physical effects
- Physical euphoria - This effect is generally quite mild.
- Difficulty urinating
- Nausea
- Dizziness
- Headaches
- Spontaneous tactile sensations
- Stimulation
- Appetite suppression
Cognitive effects
- Anxiety
- Psychosis - At very high doses, efavirenz may cause a psychotic state.
- Unity and interconnectedness
- Confusion
- Introspection
- Dream potentiation - At non-recreational doses, efavirenz often induces strange dreams.
Visual effects
Enhancements
Distortions
- Drifting (melting, breathing, morphing and flowing)
- After images
- Colour replacement
- Colour shifting
- Recursion
- Scenery slicing
- Symmetrical texture repetition
- Tracers
Hallucinatory states
- Transformations
- Internal hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)
- External hallucinations (autonomous entities; settings, sceneries, and landscapes; alterations in perspective and scenarios and plots)
Auditory effects
Toxicity and harm potential
Methadone has a moderate toxicity relative to dose. Like many HIV medications, efavirenz may cause liver toxicity at high doses or after chronic use.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
Efavirenz is not known to be habit-forming. While developing a tolerance to efavirenz is extremely rare, abusing efavirenz may cause HIV to become resistant to the drug and increase the viral load in patients with HIV.
Dangerous interactions
As efavirenz may cause hepatoxicity at high doses or after chronic use, it is not recommended to take this substance concurrently with other substances that may cause hepatoxicity. Efavirenz is an inducer of the CYP2B6 and CYP3A4 enzymes of the cytochrome P450 system, and as a result may change the metabolism of drugs metabolized by them. Consuming garlic may decrease serum levels of efavirenz.
Serotonin syndrome risk
Efavirenz is a weak serotonin reuptake inhibitor, so it is possible that combining heavy doses of efavirenz and the substances listed below may result in serotonin syndrome. Combinations with the following substances can cause dangerously high serotonin levels. Serotonin syndrome requires immediate medical attention and can be fatal if left untreated.
- MAOIs - Such as banisteriopsis caapi, syrian rue, phenelzine, selegiline, and moclobemide.[5]
- Serotonin releasers - Such as MDMA, 4-FA, methamphetamine, methylone and αMT.
- SSRIs - Such as citalopram and sertraline
- [[Wikipedia:SNRIs|DangerousInteraction::SNRIs]] - Such as tramadol and venlafaxine
- 5-HTP
Legal issues
Efavirenz is not known to be illegal in any jurisdictions, and is considered a prescription only medication.
See also
External links
References
- ↑ Apostolova, N., Funes, H. A., Blas-Garcia, A., Galindo, M. J., Alvarez, A., Esplugues, J. V. (October 2015). "Efavirenz and the CNS: what we already know and questions that need to be answered". The Journal of Antimicrobial Chemotherapy. 70 (10): 2693–2708. doi:10.1093/jac/dkv183. ISSN 1460-2091.
- ↑ Efavirenz PubChem | https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=64139
- ↑ Neuropsychopharmacology | http://www.nature.com/npp/journal/v38/n12/full/npp2013135a.html
- ↑ http://clinchem.aaccjnls.org/content/52/5/896
- ↑ Gillman, P. K. (2005). "Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity". British Journal of Anaesthesia. 95 (4): 434–441. doi:10.1093/bja/aei210 . eISSN 1471-6771. ISSN 0007-0912. OCLC 01537271. PMID 16051647.